首页> 美国卫生研究院文献>Journal of Clinical Laboratory Analysis >Development of a highly sensitive and specific two‐site enzyme immunoassay for parathyroid hormone (1‐34): Application to pharmacokinetic study on intranasal parathyroid hormone (1‐34) in human
【2h】

Development of a highly sensitive and specific two‐site enzyme immunoassay for parathyroid hormone (1‐34): Application to pharmacokinetic study on intranasal parathyroid hormone (1‐34) in human

机译:甲状旁腺激素(1-34)的高灵敏度和特异性两点酶免疫测定方法的开发:在人鼻内甲状旁腺激素(1-34)的药代动力学研究中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A highly sensitive and specific two‐site enzyme immunoassay for parathyroid hormone (1‐34) (PTH(1‐34)) and its usability for the pharmacokinetic study are described. Plasma samples were incubated simultaneously with 2,4‐dinitrophenylated anti‐PTH(1‐34) IgG and anti‐PTH(1‐34) Fab′‐ β‐ ‐galactosidase conjugate. The immune complex formed of the three components was trapped onto (anti‐2,4‐dinitrophenyl group) IgG‐coated polystyrene balls. β‐ ‐ Galactosidase activity bound to the polystyrene balls was assayed by fluorometry. The practical detection limit of PTH(1‐34) was 50 fg (12 amol)/0.05 ml of sample and 1 pg/ml as the concentration and practically no interference occurred by PTH(1‐84) and PTH‐related protein (1‐34) up to 300 pg/ml and 10 ng/ml, respectively. The application of this method has enabled us to directly estimate the bioavailability of PTH(1‐34) dosed intranasaly at the prescribed level (0.090 mg). The pharmacokinetic parameters of the intranasal PTH(1‐34) (n = 4) thus estimated were as follows: the area under the plasma concentration‐time curve (AUC) = 20,500 ± 15,900(SD) pg·min/ml; the mean residence time (MRT) = 194 ± 16.3(SD) min; and the maximal concentration (Cmax) = 98 ± 51(SD) pg/ml with the maximal time (Tmax) = 35.0 ± 12.2(SD) min. J. Clin. Lab. Anal. 12:268–275, 1998. © 1998 Wiley‐Liss, Inc.
机译:描述了甲状旁腺激素(1-34)(PTH(1-34))的高灵敏度和特异性两点酶免疫测定及其在药代动力学研究中的可用性。将血浆样品与2,4-二硝基苯基化的抗PTH(1-34)IgG和抗PTH(1-34)Fab'-β-半乳糖苷酶偶联物同时孵育。由这三种成分形成的免疫复合物被困在(抗2,4-二硝基苯基)IgG包被的聚苯乙烯球上。通过荧光法测定了与聚苯乙烯球结合的β-半乳糖苷酶活性。 PTH(1-34)的实际检出限为50 fg(12 amol)/0.05 ml样品,浓度为1 pg / ml,并且PTH(1-84)和PTH相关蛋白几乎没有干扰(1 ‐34)分别高达300 pg / ml和10 ng / ml。该方法的应用使我们能够直接估计以规定水平(0.090 mg)鼻内给药的PTH(1-34)的生物利用度。鼻内PTH(1-34)(n = 4)的药代动力学参数如下:血浆浓度-时间曲线下面积(AUC)= 20,500±15,900(SD)pg·min / ml;平均停留时间(MRT)= 194±16.3(SD)min;最大浓度(Cmax)= 98±51(SD)pg / ml,最大时间(Tmax)= 35.0±12.2(SD)min。 J.临床实验室肛门12:268-275,1998.©1998 Wiley-Liss,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号